CenterWatch publishes new, expanded guides for CRAs and CRCs

BOSTON--(BUSINESS WIRE)-- CenterWatch, a leading publisher in the clinical trials industry, announced today the release of newly revised and expanded editions of two of its top-selling training resources—The CRA’s Guide to Monitoring Clinical Trials, 3rd Edition, and The CRC’s Guide to Coordinating Clinical Trials, 2nd Edition.

These comprehensive and informative guides provide educational information and tools for novice and experienced clinical research associates and study coordinators. The guides are used extensively in university degree programs, training workshops and in certification programs.

First published in 2002 by industry experts Karen E. Woodin, Ph.D. and John C. Schneider, The CRA’s Guide includes new section review exercises and thoroughly updated content with new chapters on CRA roles and responsibilities, monitoring for device and biologic trials, globalization of studies and issues in Electronic Data Capture (EDC).

“There is a continual focus on patient safety and GCP [Good Clinical Practice],” said Carol Radochonski, R.N. B.S., CCRA, associate director of clinical operations at Quintiles. “The chapters are broken down into easy-to-understand, practical and needed skills and how to implement them. I have recommended [The CRA’s Guide] more times than I can count; it is truly a wealth of information.”

The CRC’s Guide, also written by Woodin, has been one of the foremost training tools and reference guides for study coordinators since 2004 and now includes new chapters on investigational product accountability, device and biologics trials and data safety monitoring boards.

With helpful tips and strategies, checklists, personal experiences and key takeaways on subjects ranging from study initiation, patient recruitment and informed consent to adverse events, audits and IRBs, these must-have training tools provide a step-by-step approach to monitoring and coordinating successful clinical trials.

“As the global clinical trials landscape evolves, it is critical for clinical research coordinators and study monitors to stay informed and up-to-date on critical trends, new regulations, changing practices and new technologies that each impact how to manage and conduct trials in an efficient and ethical manner,” said Joan Chambers, COO for CenterWatch. “These new editions of our top-selling training guides have been much anticipated given all of the changes that are unfolding.”

Both guides are available for purchase at http://store.centerwatch.com along with the entire Clinical Research Training Guide series. For information on quantity discounts and custom covers, email [email protected].

About CenterWatch

Founded in 1994, CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, business development leads for contract service providers, career opportunity postings, listings of clinical trials actively seeking patients, advertising and promotional opportunities, and proprietary business analysis and data about the global clinical trials industry. Visit www.centerwatch.com.



CONTACT:

CenterWatch
Cheryl Appel Rosenfeld, 617-948-5172
Editor-in-Chief
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Other Health  Communications  Research  Publishing  Science

MEDIA:

Logo
 Logo

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.